Biosyngen Pte. Ltd. is an Immuno-Oncology company committed to developing and bringing new, innovative immunotherapeutic products, such as BRG01, to patients by conducting clinical trials and obtaining approval by the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA). Participation in one of our clinical trials is currently the most appropriate way to access our investigational medical products.

Expanded access, sometimes called “compassionate use”, is a potential pathway for a patient with a serious or life-threatening disease with no or limited treatment options to try an investigative medical product for treatment. Currently, Biosyngen Pte. Ltd. is unable to offer an expanded access program for our investigational medical products, including BRG01.

We understand patient interest in accessing our immune-oncology products prior to regulatory approval. To learn more about availability of our clinical trials, please visit website at: https://www.biosyngen.com/  and contact us at: info@biosg.com for more information.